Farxiga Pipeline and Next-Gen: FDA Approvals, Label Updates, and What's Coming

The Regulatory Timeline: How Farxiga Got to Three Indications

Dapagliflozin received its first FDA approval on January 8, 2014, under NDA 202293, as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes [1]. That initial label covered 5 mg and 10 mg once-daily doses, and it carried a restriction against use in patients with an eGFR below 60 mL/min/1.73 m² for glucose-lowering purposes.

The Path From Glucose to Cardiovascular Outcomes

The glucose-lowering indication alone would not have made dapagliflozin a regulatory standout. The 2020 and 2021 expansions changed the drug's entire commercial and clinical identity.

On May 5, 2020, FDA approved Farxiga for reducing the risk of cardiovascular death and worsening heart failure in adults with heart failure with reduced ejection fraction (HFrEF), independent of whether the patient had type 2 diabetes [2]. This was the first SGLT2 inhibitor approval tied directly to a non-glycemic cardiac outcome. The approval was anchored to the DAPA-HF trial (N=4,744), published in the New England Journal of Medicine in 2019, which showed a 26% relative risk reduction (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001) in the composite of CV death, worsening HF, or hospitalization for HF [3].

The CKD Expansion and Its eGFR Threshold

On April 30, 2021, FDA approved a third indication: reducing the risk of sustained eGFR decline of at least 50%, end-stage kidney disease, cardiovascular death, or hospitalization for heart failure in adults with CKD at risk of progression [4]. The DAPA-CKD trial (N=4,304) underpinned this approval. Dapagliflozin 10 mg reduced the primary composite endpoint by 39% (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) compared with placebo [5]. Critically, the benefit extended to patients without type 2 diabetes, a population that had historically lacked approved RASS-sparing options for CKD progression.

The current label permits use in patients with eGFR ≥25 mL/min/1.73 m², a significant downward revision from the original 60 mL/min cutoff for the diabetes indication [6].

What the Current Farxiga Label Actually Says

The prescribing information for Farxiga, last substantively updated in 2021, specifies dosing, contraindications, and risk mitigation in ways that differ meaningfully from the early 2014 label [6].

Dosing by Indication

For type 2 diabetes, the starting dose is 5 mg once daily in the morning, with or without food, titrated to 10 mg once daily for additional glycemic control. For HFrEF and CKD, the approved and studied dose is 10 mg once daily. No dose adjustment is required for hepatic impairment of any severity; however, the label advises against initiating therapy for glucose-lowering if eGFR falls below 45 mL/min/1.73 m², though treatment initiated earlier may be continued.

Key Contraindications and Warnings

The label lists dialysis-dependent ESRD and a history of serious hypersensitivity reactions to dapagliflozin as absolute contraindications [6]. Warnings include:

• Diabetic ketoacidosis (DKA): Cases have occurred at glucose levels below 250 mg/dL (euglycemic DKA). Patients undergoing major surgery or prolonged fasting should hold dapagliflozin for at least 3 days before elective procedures [6].
• Fournier's gangrene: Post-marketing reports of this necrotizing fasciitis of the perineum have been identified across the SGLT2 class [7].
• Volume depletion: Particularly relevant in elderly patients or those on loop diuretics; the label recommends assessing volume status before initiating therapy.
• Lower-limb amputation: The original 2018 label addition of an amputation warning was not carried forward to Farxiga after AstraZeneca's regulatory review showed the signal was stronger for canagliflozin than for dapagliflozin [6].

The FDA's MedWatch adverse event database and the Sentinel System continue to monitor SGLT2 class effects, including urinary tract infections, genital mycotic infections, and rare cases of acute kidney injury on initiation [8].

DAPA-HF: The Trial That Reshaped the Heart Failure Label

DAPA-HF was a multicenter, randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine on November 21, 2019 [3]. The trial enrolled 4,744 patients with NYHA class II, III, or IV heart failure and a left ventricular ejection fraction of 40% or below. Patients received dapagliflozin 10 mg once daily or matching placebo on top of standard therapy.

Primary Endpoint Results

The primary composite endpoint (CV death, worsening HF, or hospitalization for HF) occurred in 16.3% of the dapagliflozin group versus 21.2% of the placebo group over a median follow-up of 18.2 months (HR 0.74; 95% CI 0.65 to 0.85; P<0.001) [3]. The number needed to treat to prevent one primary event was approximately 21.

Subgroup Findings That Extended the Label

The benefit was consistent regardless of diabetes status. Among patients without diabetes (42% of the trial), the HR was 0.73 (95% CI 0.60 to 0.88), nearly identical to the diabetic subgroup [3]. This consistency was the pharmacological basis for FDA approving the indication without a diabetes restriction.

The EMPEROR-Reduced trial with empagliflozin later confirmed the class effect, but DAPA-HF was the first to reach FDA approval in this space [9].

What DAPA-HF Did Not Show

DAPA-HF was not powered for all-cause mortality as a primary endpoint. All-cause mortality trended lower with dapagliflozin (HR 0.83; 95% CI 0.71 to 0.97), but the trial pre-specified the composite as primary. The FDA label accordingly specifies the approved claim as CV death and worsening HF, not all-cause mortality reduction [6].

DAPA-CKD: Renal Outcomes and the Landmark 2021 Approval

DAPA-CKD enrolled 4,304 adults with CKD stages 2 to 4 (eGFR 25 to 75 mL/min/1.73 m²) and a urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g [5]. Two-thirds of participants had type 2 diabetes; one-third did not.

Trial Results and Early Termination

The trial was stopped early by the independent data monitoring committee after a median follow-up of 2.4 years because of overwhelming efficacy. The primary endpoint (sustained ≥50% eGFR decline, ESRD, CV death, or renal death) occurred in 9.2% of dapagliflozin patients versus 14.5% of placebo patients (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [5]. The kidney-specific composite (excluding CV death) showed an HR of 0.56 (95% CI 0.45 to 0.68) [5].

Non-Diabetic CKD Subgroup

Among the 1,398 patients without diabetes, dapagliflozin reduced the primary composite by 50% (HR 0.50; 95% CI 0.35 to 0.72) [5]. This finding was notable because no oral agent had previously demonstrated statistically significant kidney-protective effects in non-diabetic CKD outside of RAAS inhibition. The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD subsequently elevated SGLT2 inhibitors to a Tier 1 recommendation alongside metformin and RAAS blockers [10].

Post-Market Surveillance: What FDA's Sentinel Program Has Found

The FDA Sentinel System, a distributed database covering more than 100 million Americans, has generated several important post-market signals for the SGLT2 class since 2014 [8].

DKA Signal and Label Evolution

By 2015, FDA had received enough MedWatch reports of euglycemic DKA to issue a Drug Safety Communication requiring label changes across all approved SGLT2 inhibitors [7]. For dapagliflozin, the updated label specifies that DKA has occurred at blood glucose concentrations below 250 mg/dL and that the condition may present atypically, delaying diagnosis [6]. A 2020 Sentinel analysis found the absolute DKA rate among SGLT2 users with type 2 diabetes was approximately 2.2 events per 1,000 person-years, higher than in matched DPP-4 inhibitor users [8].

Fournier's Gangrene: A Rare but Severe Signal

In August 2018, FDA issued a safety communication identifying 12 cases of Fournier's gangrene across the SGLT2 class in a 5-year period, with one fatality [7]. A subsequent pharmacoepidemiological study using the FDA Adverse Event Reporting System (FAERS) found a disproportionate signal for dapagliflozin and empagliflozin, with reporting odds ratios above 12 compared with other antidiabetic classes [11]. Absolute risk remains very low, estimated at fewer than 1 case per 25,000 patient-years, but the severity of the condition justifies the prominent label warning.

Urinary Tract and Genital Infections

Genital mycotic infections occur in approximately 6 to 8% of women and 3 to 4% of men on dapagliflozin in randomized trial data, compared with 1 to 2% on placebo [6]. Serious UTIs, including urosepsis and pyelonephritis, were identified as a class-wide concern in a 2015 FDA Drug Safety Communication [7]. The Farxiga label recommends prompt evaluation and temporary discontinuation if serious upper urinary tract infection is suspected.

The Emerging Pipeline: What Could Expand the Farxiga Label Next

Three clinical programs stand out as the most likely candidates to generate additional label expansions for dapagliflozin through 2027.

Heart Failure With Preserved Ejection Fraction (HFpEF)

The DELIVER trial (N=6,263) evaluated dapagliflozin 10 mg once daily in patients with heart failure and an ejection fraction above 40%, published in the New England Journal of Medicine in 2022 [12]. The primary composite (CV death, worsening HF, or hospitalization for HF) occurred in 16.4% of the dapagliflozin group versus 19.5% of placebo (HR 0.82; 95% CI 0.73 to 0.92; P<0.001) [12]. AstraZeneca filed a supplemental NDA based on DELIVER, and FDA approved the expanded HFpEF indication in September 2022, broadening the heart failure label to cover nearly the entire ejection fraction spectrum [2].

A pooled analysis of DAPA-HF and DELIVER (N=11,007) confirmed that benefit was consistent across the full range of ejection fractions tested (HR 0.77; 95% CI 0.70 to 0.84) [13].

Metabolic Dysfunction-Associated Steatohepatitis and CKD

Patients with metabolic dysfunction-associated steatohepatitis (MASH) frequently develop CKD through shared inflammatory pathways. Early-phase data from a 24-week proof-of-concept study showed dapagliflozin 10 mg reduced liver stiffness by 1.8 kPa and serum ALT by 18% relative to placebo in 84 patients with biopsy-confirmed MASH [14]. A Phase 3 registration trial anchored to liver biopsy histology endpoints has not yet been initiated, but AstraZeneca has signaled interest in the MASH-CKD intersection as a regulatory opportunity given the recent FDA approval of resmetirom for MASH.

Acute Kidney Injury Prevention in High-Risk Surgical Patients

Pre-clinical and early clinical data suggest that dapagliflozin's effects on tubular oxygen consumption may reduce susceptibility to ischemia-reperfusion injury [15]. A Phase 2 randomized trial (NCT04931589) is evaluating peri-operative dapagliflozin in patients undergoing cardiac surgery with cardiopulmonary bypass, with acute kidney injury as the primary endpoint. Results are expected in 2025.

Comparator Position: Where Dapagliflozin Sits Among SGLT2 Inhibitors

Dapagliflozin, empagliflozin (Jardiance), and canagliflozin (Invokana) share the same mechanism but carry distinct trial-derived indication profiles.

FDA Indication Comparison

Empagliflozin was the first SGLT2 inhibitor to receive an FDA cardiovascular outcomes approval (2016, based on EMPA-REG OUTCOME, N=7,020), demonstrating a 38% relative reduction in CV death [9]. Canagliflozin received a CV outcomes approval in 2018 based on CANVAS (N=10,142) but carries a black-box warning for lower-limb amputation that dapagliflozin's label does not [16].

Dapagliflozin is the only SGLT2 inhibitor with an FDA-approved label covering both HFrEF and HFpEF across the full ejection fraction range, following the September 2022 DELIVER-based expansion [2].

Kidney Outcomes Across the Class

Both dapagliflozin (DAPA-CKD) and empagliflozin (EMPA-KIDNEY, N=6,609) have demonstrated significant renal protection in CKD patients without diabetes [17]. EMPA-KIDNEY showed a 28% reduction in the primary kidney disease progression or CV death composite (HR 0.72; 95% CI 0.64 to 0.82; P<0.001), broadly consistent with DAPA-CKD's 39% reduction [17]. The two trials used different eGFR enrollment thresholds (eGFR ≥20 in EMPA-KIDNEY vs. ≥25 in DAPA-CKD), making direct comparison imprecise.

Clinician and Guideline Perspectives on Dapagliflozin's Evolving Role

The 2022 AHA/ACC/HFSA Heart Failure Guidelines gave SGLT2 inhibitors, including dapagliflozin, a Class I recommendation (Level of Evidence A) for patients with HFrEF to reduce the risk of HF hospitalization and CV death [18]. The guideline document states: "In patients with symptomatic chronic HFrEF, SGLT2 inhibitors are recommended to reduce HF hospitalization and CV mortality, irrespective of the presence of type 2 diabetes." [18]

The 2022 KDIGO CKD Guideline similarly recommends: "We recommend treating patients with type 2 diabetes and CKD with an SGLT2 inhibitor if eGFR is ≥20 mL/min/1.73 m²." [10] The guideline extends a conditional recommendation to CKD patients without diabetes based primarily on DAPA-CKD's non-diabetic subgroup data [10].

A HealthRX review of the prescribing patterns reported in the 2024 AstraZeneca global outcomes data suggests that real-world dapagliflozin use in CKD without diabetes remains substantially below guideline-recommended levels, with estimates of under 15% of eligible patients receiving a prescription within 12 months of a qualifying CKD diagnosis.

How to Use the Current Farxiga Label in Practice

Clinicians initiating dapagliflozin for HF or CKD should confirm eGFR is at or above 25 mL/min/1.73 m² before prescribing [6]. Volume status assessment before the first dose reduces early acute kidney injury risk, particularly in patients already on ACE inhibitors, ARBs, and loop diuretics in combination.

Pre-Prescription Checklist

Before writing the prescription, verify these four items:

1. EGFR ≥25 mL/min/1.73 m² (any indication) or ≥45 mL/min/1.73 m² if initiating solely for glucose lowering.
2. No current dialysis dependence.
3. No history of recurrent genital or urinary tract infections that could be exacerbated.
4. Surgical procedures planned within 3 to 4 weeks: hold dapagliflozin at least 3 days before elective surgery to reduce DKA risk [6].

Monitoring Parameters After Starting

Check serum creatinine, eGFR, and electrolytes 2 to 4 weeks after initiation. A transient 5 to 10% dip in eGFR is expected and does not require discontinuation; this hemodynamic effect is distinct from structural nephrotoxicity and generally reverses over 8 to 12 weeks [5]. Educate patients to report perineal pain or swelling immediately given the rare but serious Fournier's gangrene risk [7].

The recommended maintenance dose for HF and CKD remains 10 mg once daily, taken in the morning with or without food, as studied in DAPA-HF and DAPA-CKD [3][5].